USPTO Proposes Phillips-Type Claim Construction For Post Grant Proceedings at the PTAB
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
The USPTO published a Notice of Proposed Rulemaking on May 9, 2018 seeking to change the claim construction standard for PTAB trials from the current broadest reasonable interpretation (BRI) to the claim construction standard applied in federal courts and ITC proceedings that follow Phillips v. AWH Corp., 415 f .3d 1303 (Fed. Cir. 2005) (en banc). The proposed rule also requires the PTAB to consider prior claim construction determinations that are timely made of record from a civil action or ITC proceeding.
The differences between the current and proposed rule for IPRs are shown below:
Similar amendments are proposed to 37 C.F.R. § 42.200(b) for post-grant review proceedings and 35 C.F.R. § 42.300(b) for covered business method review proceedings.
The USPTO indicated that this change in claim construction standard would be applied to all pending IPR, PGR, and CBM proceedings before the PTAB.
The deadline to submit written comments on the proposed rulemaking is July 9, 2018.
The Notice is available at https://www.gpo.gov/fdsys/pkg/FR-2018-05-09/pdf/2018-09821.pdf.
Written by: Nathanael Luman, Ph.D. and Kerry S. Taylor, Ph.D.
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…